PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
21-Jan-2021 Sprint #4 Workshop: Bridging the silos between Clinical Research, eHealth & Digital Therapeutics - “The rise of patient-centric applications” Innovation Sprint
21-Jan-2021 HumanOptics AG: Request by the main shareholder to execute a merger squeeze-out HumanOptics AG
21-Jan-2021 ProBioGen Licenses GlymaxX® Technology to AbbVie B3C newswire
21-Jan-2021 Xellia Pharmaceuticals joins Medicines for Europe to support better access to critical medicines Xellia Pharmaceuticals
21-Jan-2021 Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patients Newron
21-Jan-2021 Scottish Medicines Consortium Accepts Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients in Scotland with Newly Diagnosed Multiple Myeloma Janssen Pharmaceutical Companies of Johnson & Johnson
21-Jan-2021 New CRO from China joins Repositive Cancer Model network, increasing model database size by 87% Repositive
21-Jan-2021 NICE RECOMMENDS JYSELECA®▼ (FILGOTINIB) ON NHS IN ‘LANDMARK’ DECISION FOR RHEUMATOID ARTHRITIS Gilead Sciences, Inc.
21-Jan-2021 Nexelis acquires the GSK vaccines clinical bioanalytical laboratory located in Marburg – Germany and enters into a 5-year strategic agreement with GSK. Nexelis
21-Jan-2021 ALLIANCE PHARMA PLC - Full Year Trading Update ALLIANCE PHARMA PLC
21-Jan-2021 Efficacy of Veklury® (remdesivir) against new SARS-CoV-2 variants Gilead Sciences
21-Jan-2021 Epigenomics AG Plans to Challenge NCD Decision and Unveils Its Next Generation Liquid Biopsy Test for Colorectal Cancer Screening Epigenomics AG
21-Jan-2021 Domainex expands executive team to support ongoing growth Sciad Newswire
21-Jan-2021 Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patients Newron Pharmaceuticals S.p.A.
21-Jan-2021 The Zur Rose Group accelerates growth Zur Rose Group AG
21-Jan-2021 Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM RELIEF THERAPEUTICS Holdings AG
20-Jan-2021 NICE RECOMMENDS KITE’S TECARTUS®▼ FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY INCLUDING A BRUTON’S TYROSINE KINASE (BTK) INHIBITOR IN ENGLAND WITHIN THE CANCER DRUGS FUND Kite, a Gilead Company
20-Jan-2021 MaxCyte, Inc. Trading Update MaxCyte, Inc.
20-Jan-2021 Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMT Tiziana Life Sciences
20-Jan-2021 Impel NeuroPharma Announces U.S. Food & Drug Administration Acceptance of New Drug Application for INP104 for the Acute Treatment of Migraine Impel NeuroPharma